I51.3 I21
Conditions
Interventions
Group 1: Patients with ventricular thrombus after acute myocardial infarction (MI) and Marcumar between 2008 and 2022
Group 2: Patients with ventricular thrombus fter acute myocardial infarction (MI)
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Age = 18 years - Myocardial infarction (STEMI or NSTEMI) with PCI prior to diagnosis of the ventricular thrombus and within the same hospitalization - Ventricular thrombus confirmed by TTE and/or cardiac MR - Initiation of oral anticoagulation treatment
Exclusion criteria
Exclusion criteria: - Patients with anticoagulation therapies other than DOAC or Marcumar
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Incidence of patients with left ventricular thrombus after myocardial infarction • Prescribed antithrombotic therapy • Change of size and thrombus modification of ventricular thrombi under oral anticoagulation therapy with DOACs or Marcumar based on a follow-up examination with TTE or cardiac MRI in the first 3 to 6 months from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical outcomes: • Documented/reported embolic events (stroke, myocardial infarction) • Documented/reported bleeding events • Documented/reported death during the first 12 months after diagnostic confirmation of the ventricular thrombus and initiation of anticoagulation | — |
Countries
Germany
Contacts
Public ContactChristoph Olivier
Universitätsklinikum Freiburg
Outcome results
None listed